Bdd Vs Step Proxima Cro

Proxima Cro Logo 2 Swpdc Rob maccuspie, regulatory manager at proxima clinical research, is here to discuss the similarities and differences between two major fda submission programs: breakthrough device designation (bdd) and the safer technologies program (step)!. Today we're going to dive into the world of bdd and step to give you a better understanding of each program and cover their differences and where they overlap. let's start with the bdd.

Bdd Vs Step Rob maccuspie, regulatory manager at proxima clinical research, is here to discuss the similarities and differences between two major fda submission programs. What are the differences, similarities, and potential benefits of fda’s breakthrough devices program (bdp) and safer technologies program for medical devices (step)? in this episode of the global medical device podcast, jon speer talks to isabella schmitt, director of regulatory affairs for proxima clinical research (cro). Wondering whether fda’s breakthrough device designation or step program is worth the effort? this pocket guide unpacks the program in plain english—what it is, who qualifies, and exactly how it can slash review delays, unlock cms reimbursement shortcuts, and impress investors. The tap pilot aims to foster early engagement between device sponsors and the fda, improve the quality of submissions, and streamline the review process by addressing potential issues proactively.

Proxima Cro Proxima Cro Wondering whether fda’s breakthrough device designation or step program is worth the effort? this pocket guide unpacks the program in plain english—what it is, who qualifies, and exactly how it can slash review delays, unlock cms reimbursement shortcuts, and impress investors. The tap pilot aims to foster early engagement between device sponsors and the fda, improve the quality of submissions, and streamline the review process by addressing potential issues proactively. Unlike bdd, step eligible devices may include those intended to treat or diagnose non life threatening or reasonably reversible diseases or conditions. Isabella schmitt, director of regulatory affairs at proxima, is here to help webinar participants demystify bdd and step by explaining the application processes and why getting these designations early in the regulatory process can help clear your device’s pathway to approval. Dedicated clinical research organization (cro) to the new class of rising stars in drugs, devices, diagnostics and digital health. Learn about the difference between bdd vs. step, the criteria for each program, the benefits, and the overall process.